Wolfe Research Upgrades Janux Therapeutics to Outperform on Upcoming Autoimmune Data
Wolfe Research upgrades Janux Therapeutics to Outperform with a $23 target. Q4 autoimmune data for JANX011 cited as key catalyst, 32% upside.
/ 1648 items
#XY↓
Morgan Stanley Initiates Q32 Bio at Overweight with $34 Target — 113% Upside Potential
Morgan Stanley initiates Q32 Bio at Overweight ($34 target) as bempikibart matches JAK efficacy in alopecia areata while offering cleaner safety, less monitoring and durability.
Vanda Pharmaceuticals Receives First EU Orphan Designation for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals receives the first EU orphan designation for imsidolimab to treat rare, life-threatening GPP. FDA decision due Dec 12, 2026.
FDA Places Clinical Hold on REGENXBIO’s Gene Therapy for Hunter Syndrome
FDA places clinical hold on REGENXBIO’s RGX-121 for Hunter Syndrome after asymptomatic spine MRI findings in 5 patients. Patients remain well; no near-term BLA resubmission.
Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets
Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.
Alvotech Partners with Lotus on Biosimilars to Imfinzi and Hemlibra in the US and Asia
Alvotech partners with Lotus for biosimilars to Imfinzi and Hemlibra in the US and Asia. Deal worth up to $150M plus ongoing supply revenue.